View the chart data
| Period | Gross margin |
|---|---|
| 2025 second quarter | 43.6% |
| 2026 second quarter | 30.1% |
NEXGEL (Nasdaq: NXGL) put a one-for-20 reverse stock split into effect on October 12. The medical-products company is trying to regain compliance with Nasdaq’s minimum share-price requirement. Combining shares addresses that listing problem, while a proposed business reorganization raises a separate question: how much of the company will current shareholders still own? [1][6]
That distinction matters for this small U.S.-listed company. Today’s split changes its share count. The broader plan would change its financing, operating assets and ownership. Those changes carry different consequences for NXGL investors.
What changes with today’s shares
Nasdaq’s October 8 corporate-action notice confirmed the split’s October 12 effective date. The issuer says the shares retain the NXGL symbol on the Nasdaq Capital Market. Each group of 20 existing shares has become one share, with fractional entitlements rounded up to a whole share. [2][1]
The company reported approximately 487,384 shares outstanding after the combination, before fractional-share rounding. The aim is a higher per-share trading price to help meet Nasdaq’s $1 minimum bid requirement. NEXGEL explicitly cautions that regaining or maintaining compliance is not assured. [1]
A medical-products expansion has taken longer
Behind the stock-market action is a company moving beyond its longstanding hydrogel business. Hydrogels are water-rich materials used in products such as wound dressings and skin patches. NEXGEL also manufactures products for other consumer-healthcare companies. [5]
Its Bionx Surgical division sells products that include human-tissue grafts and connective-tissue material, alongside an antimicrobial hydrogel dressing. Its eye-care portfolio includes tissue grafts derived from placentas. These products give the business a more specialized medical focus than consumer skin-care brands alone. [5]
In its August 17 results, NEXGEL said the rollout after acquiring assets from Celularity had been slower than anticipated. Manufacturing constraints were affecting product availability, and the surgical business had about $795,000 of unfilled orders. That was an August-reported backlog, not evidence that those sales have since been delivered. [3]
Second-quarter sales were approximately $3.69 million, while the net loss was $2.87 million. The loss included acquisition-related amortization, which spreads asset costs over time, and other non-cash or one-time items. Those qualifications help explain the loss without removing the need for stronger operating performance. [3]
Growing sales have not resolved the cash problem
The June-quarter filing shows the pressure underneath those sales: gross margin fell from 43.6% a year earlier to 30.1%. Lower-margin biomaterial sales, inventory write-offs, freight and royalty costs reduced what remained after product costs. Less money was therefore available to cover the rest of the business. [4]
The same filing disclosed substantial doubt about NEXGEL’s ability to keep operating. It reported roughly $0.5 million of unrestricted cash at June 30 and $2.7 million used in operations over the first half. Those are historical balances and cash flows, rather than a measurement of today’s available funds. [4]
The proposed reset carries an ownership cost
In September’s shareholder presentation, management proposed combining NEXGEL with operating assets from Fountainhead LifeSciences, raising approximately $5 million and restructuring its balance sheet. The idea is to bring manufacturing and sales into one platform. Fountainhead is owned by NEXGEL’s interim chief executive, making independent review of the related-party proposal especially consequential. [6]
“The proposed transaction would materially dilute existing common shareholders.”
Strategic Review & Proposed Platform Reorganization · September 2026 [6]
The illustrative plan leaves existing common shareholders with approximately 5% ownership after the proposed transactions. That is a preliminary scenario, not a completed transaction. Financing, audits, independent valuation, agreements and required approvals remain conditions. [6]
Today’s reverse split advances NEXGEL’s attempt to retain its listing. The business outcome still depends on improving supply, earning more from sales and securing financing. For existing shareholders, the unresolved terms of the proposed reorganization may matter far more than the smaller share count.